SeaSpine Announces Full Commercial Launch of the Mariner MIS Wayfinder System
01 November 2022 - 7:05AM
SeaSpine Holdings Corporation (NASDAQ: SPNE), a global medical
technology company focused on surgical solutions for the treatment
of spinal disorders, today announced the full commercial launch of
the Mariner® MIS Wayfinder System.
Mariner MIS Wayfinder is a novel, one step, k-wireless screw
delivery system for pedicle screw fixation. Mariner MIS
Wayfinder eliminates reliance on traditional guidewires for
percutaneous screw placement by providing a fully integrated,
surgeon-led solution that leverages the strength and versatility of
SeaSpine’s foundational Mariner modular pedicle screw
technology.
Mariner MIS Wayfinder is fully integrated with the 7D FLASH™
Navigation System’s recently launched FLASH Percutaneous module.
FLASH Percutaneous addresses the minimally invasive spine surgery
market and facilitates a fast, efficient, and simple workflow that
complements Mariner MIS Wayfinder’s all-in-one modality, making it
an optimal solution for MIS spinal fusion procedures.
“Thoughtful and efficient instrumentation design in Mariner MIS
Wayfinder delivers the capability to significantly reduce the
number of steps associated with fixation placement,” said Azam
Basheer, M.D., Neurosurgeon at Henry Ford Health in Jackson, MI.
“Combined with the outstanding functionality of Mariner MIS and
FLASH Navigation’s recently-launched percutaneous module, SeaSpine
now offers a market-leading procedural solution.”
“Mariner MIS Wayfinder has been a powerful addition to the
Mariner platform,” stated Mike Hall, Vice President, Marketing.
“This effective tool is ergonomic and provides a highly
user-friendly solution for surgeons using this emerging
technique.”
About SeaSpineSeaSpine (www.seaspine.com) is a
global medical technology company focused on the design,
development, and commercialization of surgical solutions for the
treatment of patients suffering from spinal disorders. SeaSpine’s
complete procedural solutions feature its market-leading FLASH™
Navigation, a system designed to improve accuracy of screw
placement and provide a cost-effective, rapid, radiation-free
solution to surgical navigation, and a comprehensive portfolio of
spinal implants and orthobiologics to meet the varying combinations
of products that neurosurgeons and orthopedic spine surgeons need
to facilitate spinal fusion in degenerative, minimally invasive
surgery (MIS), and complex spinal deformity procedures on the
lumbar, thoracic and cervical spine. With product development
expertise in advanced optics, software, orthobiologic sciences and
spinal implants, SeaSpine can offer its surgeon customers a
complete solution to meet their patients’ evolving clinical needs.
SeaSpine currently markets its products in the United States and in
approximately 30 countries worldwide.
Forward-Looking
Statements SeaSpine cautions you that statements
included in this news release that are not a description of
historical facts are forward-looking statements that are based on
the Company’s current expectations and assumptions. Such
forward-looking statements include, but are not limited to,
statements relating to: the Mariner MIS Wayfinder System providing
a fully-integrated, surgeon-led solution that enables real-time
feedback, providing clinicians an innovative and intuitive approach
to pedicle screw fixation, providing a one-step posterior
percutaneous pedicle solution that eliminates need for stepwise
pedicle access trocars and guidewires, and offering access to a new
level of operative efficiency. Among the factors that could
cause or contribute to material differences between the Company’s
actual results and the expectations indicated by the
forward-looking statements are risks and uncertainties that
include, but are not limited to: the ability of newly launched
products, such as the Mariner MIS Wayfinder System, to perform as
designed and intended and to meet the needs of surgeons and
patients, including as a result of the lack of substantial clinical
validation of products in limited commercial (or “alpha”) launch;
the fact that newly launched products may require substantial
additional development activities, which could introduce further
expense and delay, or as a result of delay in timely obtaining
regulatory clearances; the Company’s ability to continue to invest
in medical education and training for its newly launched products,
including the Mariner MIS Wayfinder System; unexpected expense and
delay, including as a result of developing and supporting the
launch of new products; general economic and business conditions in
the markets in which the Company does business, both in
the U.S. and abroad; and other risks and uncertainties more fully
described in the Company’s news releases and periodic filings with
the Securities and Exchange Commission. The Company’s public
filings with the Securities and Exchange Commission are available
at www.sec.gov.
You are cautioned not to place undue reliance on forward-looking
statements, which speak only as of the date when
made. SeaSpine does not intend to revise or update any
forward-looking statement set forth in this news release to reflect
events or circumstances arising after the date hereof, except as
may be required by law.
Investor Relations Contact Greg
Chodaczek610-368-6505ir@seaspine.com
SeaSpine (NASDAQ:SPNE)
Historical Stock Chart
From Dec 2024 to Jan 2025
SeaSpine (NASDAQ:SPNE)
Historical Stock Chart
From Jan 2024 to Jan 2025